Clinical Trials Logo

Recurrent GBM clinical trials

View clinical trials related to Recurrent GBM.

Filter by:
  • None
  • Page 1

NCT ID: NCT05370508 Active, not recruiting - Recurrent GBM Clinical Trials

A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM

Start date: February 6, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objectives of this trial are to evaluate the safety, dose-limiting toxicities, maximum tolerated dose (MTD), maximum administered dose (MAD) and recommended Phase 2 dose (RP2D) for future study after a single treatment of SONALA-001 in combination with MRgFUS and to evaluate preliminary efficacy of sonodynamic therapy (SDT) using SONALA-001 and Exablate Type 2.0 device in subjects with progressive or recurrent GBM.

NCT ID: NCT04763031 Terminated - Glioblastoma Clinical Trials

Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT

Start date: March 5, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of the Xoft Axxent eBx System when used for single-fraction IORT for recurrent Glioblastoma. IORT using the Xoft Axxent eBx System is no worse than (non-inferior) GliaSite radiation therapy when used as stand-alone radiation treatment immediately following maximal safe neurosurgical resection in patients with recurrent glioblastoma multiforme (GBM).

NCT ID: NCT04681677 Terminated - Glioblastoma Clinical Trials

Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab

IORT
Start date: November 2, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to assess the overall survival of patients treated with the Xoft Axxent eBx System and post-radiation adjuvant Bevacizumab for single-fraction IORT following maximal neurosurgical resection of recurrent glioblastoma. A historical comparison will be made to the results of the EBRT + Bevacizumab arm of RTOG 1205.

NCT ID: NCT03068650 No longer available - Recurrent GBM Clinical Trials

Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut

CDX-110
Start date: n/a
Phase: N/A
Study type: Expanded Access

Celldex endeavors to make investigational products available to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. Requests for expanded access to rindopepimut in patients with EGFRvlll expressing recurrent glioblastoma will be considered.